This report selected the data of patients with moderate to severe plaque psoriasis treated with adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, tildrakizumab, risankizumab, secukinumab and ustekinumab public use of Catalonia (SISCAT) and that they were included in the CatSalut register of patients and treatments (RPT) from 2015. In this period, 6,800 treatments have been used to treat 4,860 patients diagnosed with plaque psoriasis. , who had an average age of 50 years and of whom 58% were men. The initial criteria set out in the Agreement have been met in 4,775 (70.2%) treatments (1st line [52%] and 2nd line and subsequent [91%]). The response rate for first-line treatments was 80.7% and for second-line treatments 77.5%. Overall, the response rate for biologic drugs was 80%, while that of aprililast was 10% lower.
Psoriasis; Biological treatments; Apremilast
Programa d'Harmonització Farmacoterapèutica. Tractament de la psoriasi en plaques: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2022.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/7116
This item appears in following collections
The following license files are associated with this item: